Personen

Prof. Dr. med. Jessica Hassel

Sektionsleiterin (Sektion Dermatoonkologie)
Arbeitsgruppenleiterin (AG Prof. Dr. J. Hassel)
Ärztliche Leitung (Dermatoonkologische Ambulanz)

06221 56-8562

Ärztlicher / Beruflicher Werdegang

seit 2017

Sektionsleitung der Sektion für DermatoOnkologie der Hautklinik im Nationalen Centrum für Tumorerkrankungen (NCT), Universitätsklinikum Heidelberg

2019

Nominierung zur ausserplanmässigen Professorin

2018

Secundo loco W2 “Klinische und molekulare Dermatologie”, Universität Duisburg-Essen

2016

Habilitation im Fach Dermatologie und Venerologie, Universität Heidelberg

2015 – 2016

Labor Sabbatical am TRON/BioNTech Mainz

2015

Zusatzbezeichnung “Palliativmedizin”

2011

Zusatzbezeichnung “Dermatohistologie”

seit 2010

Oberärztin an der Hautklinik und dem NCT, Universitätsklinikum Heidelberg

2009 – 2010

Stellvertretende Leitung der Klinischen Kooperationseinheit für Dermatoonkologie des Deutschen Krebsforschungszentrums (DKFZ), Heidelberg

2008 – 2010

Oberärztin und Wissenschaftlicher Mitarbeiter aan der KKE Dermatoonkologie, DKFZ

2007

Fachärztin für Dermatologie und Venerologie

2004 – 2007

Assistenzärztin an der Hautklinik, Städtisches Klinikum Ludwigshafen

2003 – 2004

Arzt im Praktikum am St. Vincentius Krankenhaus für Innere Medizin, Heidelberg

2002 – 2003

Postdoktorandin an der Hautklinik, Universitätsspital Zürich, Schweiz

1995 – 2002

Studium der Humanmedizin, Universität Würzburg, Staatsexamen (Note: sehr gut)
Promotion
Doktorarbeit am Institut für Physiologische Chemie, Universität Würzburg  bei Prof. Manfred Schartl „Untersuchungen zur Apoptoseregulation durch die Melanom-induzierende Rezeptortyrosinkinase Xmrk“ (Note: Summa cum laude)

Wissenschaftlicher Werdegang

2018

Secundo loco W2 “Klinische und molekulare Dermatologie”, Universität Duisburg-Essen

seit 2008

Leitung klinischer Studien, Phasen I-IV, u.a. auch der ADO, EADO, EORTC und eigene Investigator-initiierte Studien (IIT: TaMe, ELEKTRA, IRINA)

2016

Habilitation im Fach Dermatologie und Venerologie, Universität Heidelberg

2015 – 2016

Labor Sabbatical am TRON/BioNTech Mainz

2002 – 2003

Postdoktorand an der Hautklinik, Universitätsspital Zürich, Schweiz

1995 – 2002

Dissertation am Institut für Physiologische Chemie, Universität Würzburg

Auszeichnungen

2018

Deutscher Hautkrebspreis der Deutschen Hautkrebsstiftung

2015

Auszeichnung der Arbeitsgemeinschaft internistische Onkologie (AIO) als „Exzellentes Studienzentrum 2015“

2006

Promotionspreis der Universität Würzburg

Stipendien

2010 – 2012

Olympia-Morata Habilitationsstipendium der Universität Heidelberg

2008 – 2009

Fleur-Habig-Habilitationsstipendium der Hiege Stiftung gegen Hautkrebs

1995 – 2003

Stipendiatin der “Studienstiftung des deutschen Volkes”

Geförderte Projekte/Grants

2012

Sachmittelbeihilfe der DFG nachfolgend an die Nachwuchsakademie „Klinische Studien“ für die Investigator-initiierte Studie „Behandlung von Melanom-patienten mit Fernmetastasen oder nicht operablen Lymphknotenmetastasen (Stadium IV/IIIB/C) mit Tadalafil (Cialis) - Eine Pilotstudie zum “Proof of Principle”                    EudraCT Nummer: 2011-003273-28

2015

Grant Bristol Myers Squibb für die translationale Forschung in der ELEKTRA-Studie (Kombination Ipilimumab und Strahlentherapie bei Patienten mit Hirnmetastasen eines Melanoms)

2015

BMBF Juniorverbund TIL-REP, Subprojekt Melanom: „Zusammenhang von TIL Repertoire und Behandlungserfolg in Melanompatienten“

2016

DKTK Joint Funding „Paradigm – Predicting Abscopal effects after RADiotherapy and Immune-Checkpoint inhibition via integrative Genomics in Melanoma“

2016

Funding DKFZ/NCT Hipo² “Immunological profiling of tumors and identification of determinants for response to cancer immunotherapies – Subproject MIA - Mutation landscape in Melanoma under Immune checkpoint blocker treatment

2016

DKTK Joint Funding “UniCAR NK cells”

2016

NCT Elevator Pitch Funding “Sportivumab – Feasibility of Exercise as a supportive Measure for Patients undergoing Checkpoint-inhibitor Treatment”

2016

NCT- 3.0 Funding “MelTIL – TIL therapy study in melanoma”

2018

Förderung durch den Innovationsaussschuss des Gemeinsamen Bundesausschusses (GBA/DLR) für das Projekt „PEF-Immun – Partizipative Entscheidungsfindung zur Immuntherapie in der Onkologie – prospektive, randomisiert kontrollierte Studie“

2019

RTG 2099 Hallmarks of Skin Cancer, DFG, project 12 „The Role of the Immune Checkpoints LAG-3 and TIM-3 for Immunotherapy of Melanoma”

Studien

Phase 1 Trial to evaluate safety and efficiacy of repeated intralesional (lymphnode metastasis) Adeno-IL-2 in stage IV melanoma patients (Transgene), Sub-investigator (SI)

Phase 1 Trial to evaluate safety and efficacy of repeated intralesional (cutaneous lesions) Adeno-IFNgamma in cutaneous lymphoma patients (Transgene), SI

Adjuvant therapy with peg IFN-alpha versus control for 5 years in melanoma patients stage III (EORTC 18991), SI

Temodal versus Temodal plus peg IFN-alpha in stage IV melanoma patients (ADO), SI

Adjuvant therapy with low-dose IFN-alpha 18 vs 60 months in stage II-III melanoma patients (ADO), SI

Adjuvant therapy with IFN-alpha for 18 months vs peg IFN-alpha for 36 months in stage II-III melanoma patients (EADO), SI

Adjuvant therapy with low-dose INF-alpha vs peg IFN-alpha for 24 months in stage II-III melanoma patients (ADO), SI

Continous vs intermittent adjuvant medium dose INF-alpha treatment for 5 years in melanoma patients stage II, SI

Phase II trial with Peptide Vacciniation with gp100 +/- Ipilimumab vs Ipilimumab monotherapy (Medarex Mdx010-20), SI till 06/08, PI since 07/08

Phase I/II trial with DTIC +/- CNTO95 in stage IV melanoma (Centocor C1034T02), SI

Phase II trial with APO866 in stage IV melanoma patients (Apoxis AP003), SI

Phase III trial with Fotemustine i.a. vs i.v. in stage IV uvea melanoma patients with singly liver metastasis (EORTC 18021), SI till 06/08, PI since 07/08

Phase III trial with DTIC +/- Ipilimumab in stage IV melanoma patients (BMS CA 184024), SI till 06/08, PI and LKP from 07/08

Phase I trial with Bi2536 in metastasized solid tumors (EORTC 90061), SI

Phase II trial with pegylated interferon- and sorafenib in stage IV melanoma patients (SoraPeg, ADO), SI till 06/08, PI from 07/08

Phase III trial with DTIC +/- Bcl-2 antisense DNA (Genasense) in stage IV melanoma patients (Genta), SI till 06/08, PI from 07/08

Phase III trial with Paclitaxel +/- STA-4783 in stage IV melanoma patients (Synta), SI till 06/08, PI from 07/08

Phase II trial with agonistic CD137 antibody in stage IV melanoma patients (BMS CA 186006), PI

Phase III trial of an individualized sensitivity directed combination chemotherapy vs DTIC in stage IV melanoma patients (ADO), PI

Phase III trial to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma (DERMA), PI

Phase II trial to assess the efficacy of recMAGE-A3 + AS15 ASCI as palliative treatment in patients with MAGE-A3 positive stage IV melanoma (PREDICT), PI

Phase III trial with adjuvant Ipilimumab vs Placebo after complete resection of high-risk stage III melanoma (EORTC 18071, BMS184-029), PI

Phase III trial with RO5185426 (BRAF inhibitor) vs DTIC in patients with stage IIIc or IV melanoma (BRIM3), SI

Phase I trial to evaluate the safety and tolerability of AP12009 in patients with advanced tumors, SI

Phase II trial with Ipilimumab in patients with advanced melanoma and spontaneous immune response to NY-ESO-1, SI

Phase III trial with MEK114267 vs chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma (METRIC), PI

Phase III trial with BRF113683 vs chemotherapy in subjects with BRAF mutation positive advanced Stage III or IV melanoma (BREAK3), PI

Phase III trial with ABI-007 (Abraxane) vs DTIC in patients with stage IV melanoma, PI

Phase III trial with Tasigna vs DTIC in patients with metastatic and/or inoperable melanoma harbouring a c-Kit mutation (TEAM), PI

Phase II trial with E7080 in previously treated subjects with unresectable stage III or stage IV melanoma, SI

Phase III trial with Ipilimumab in previously treated stage IV melanoma patients (Multibasket-ADO), SI

Phase III trial with Ipilimumab in previously treated stage IV melanoma patients with spontaneous immune response to NY-ESO-1, SI

Phase II trial with DTIC +/- E7080 in previously untreated patients with stage IV melanoma, PI

Expanded access study of RO5185426 in patients with previously treated metastatic melanoma (BRAF-EAP), SI

Neoadjuvant treatment of locoregional metastases in melanoma with Multiferon (NAM-ADO), PI

Phase IIa study with tadalafil in patients with previously treated stage IV melanoma (TaMe), IIT, PI

Phase 3 trial with Ipilimumab in patients with metastasized melanoma stage III unresectable or stage IV 3 vs 10mg/kg (BMS184-169), PI

Phase 3 trial with Dabrafenib +/- Trametinib in patients with V600E/K positive stage III unresectable or stage IV melanoma firstline (Combi-D), PI

Phase 3 trial with Dabrafenib + Trametinib in patients with V600E/K positive stage III unresectable or stage IV melanoma vs Vemurafenib firstline (Combi-V), PI

Phase 2 trial with Vismodegib in patients with locally advanced or metastatic basal cell carcinoma (STEVIE), PI

Phase 3 trial with Vemurafenib vs Placebo adjuvant in patients with surgically-resected, cutaneous BRAF mutant melanoma at high risk for recurrence (BRIM8), PI

Phase 3 trial with Vemurafenib +/- GDC0973 in patients with V600 mutated unresectable stage III or IV melanoma firstline (COBRIM), PI

Phase 3 trial with Nivolumab vs DTIC in patients with BRAF wildtype unresectable stage III or IV melanoma firstline (BMS CA209-066), PI

Phase 3 trial with Nivolumab vs chemotherapy in patients with unresectable stage III or IV melanoma, after progression under Ipilimumab treatment (BMS CA209-037), PI

Phase 2 trial with Ipilimumab Re-treatment vs chemotherapy in patients with unresectable stage III or IV melanoma, who progressed after initially achieving disease control with ipilimumab therapy (BMS CA184-243)

Phase 3 trial with pegIFN vs observation in patients with ulcerated melanoma (EORTC18081), PI

Phase 3 trial with Dabrafenib + Trametinib vs placebo in patients with surgically-resected BRAF V600E/K mutant stage III melanoma (Combi-AD), PI

Phase 2 trial with GSK2241658A in patients with unresectable stage III or IVa melanoma which expresses NY-Eso1, PI

Phase 3 trial with MEK162 vs DTIC in patients with cutaneous NRAS-mutated unresectable stage III or IV melanoma (NEMO), PI

Phase 3 trial with LGX818 +/- MEK162 vs Vemurafenib in patients with V600E/K-mutated unresectable stage III or IV melanoma (COLUMBUS), PI

Phase 3 trial with LGX818 Mono- and resistance-directed combination treatment in patients with unresectable BRAF V600-mutated stage III or IV melanoma (LOGIC), PI

Phase 3 trial with Masitinib vs DTIC in patients with c-kit mutated unresectable stage III or IV melanoma (AB08026), PI

Phase 2 trial with LGX818/MEK162 gefolgt von einer Resistenz-bestimmten zielgerichteten Therapie nach Progression in Patienten mit Stadium III nicht resezierbar und Stadium IV (LOGIC2), PI

Prospektive randomisierte klinische Prüfung einer adjuvanten Therapie von vollständig resektiertem Merkelzellkarzinom (MCC) mit 3mg/kg Körpergewicht Ipilimumab (Yervoy®) alle drei Wochen für 12 Wochen versus Beobachtung (ADMEC; BMS184-205), PI

Phase 2 trial to investigate clinical activity and safety of MSB001718C (PD-L1 antibody) in Patienten mit metastasiertem Merkelzellkarzinom, PI

Phase 3 trial with adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0 (EORTC18081), PI

Phase 2 trial of Dabrafenib plus Trametinib in patients with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain (Combi-MB), PI

Phase 2 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Nintedanib in combination with Paclitaxel chemotherapy for the treatment of patients with BRAF wildtype metastatic melanoma (Nipawilma), PI

Phase 4 trial with Nivolumab (BMS-936558) in patients with ipilimumab refractory stage III or IV melanoma (BMS CA209-172), PI

Evaluation of the Radiotherapeutic and Immunemodulatory Response to Whole Brain Radiotherapy (WBRT) or Stereotactic Radiosurgery (SRS) in patients with brain metastases from Malignant Melanoma (MM) treated with or without Ipilimumab (IP) (ELEKTRA), IIT, PI

Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma (SUMIT), PI

Phase I first-in-human dose escalating study evaluating the safety and tolerability of intravenous administration of a tetravalent RNA-lipoplex cancer vaccine (Lipo-MERIT), PI

Phase III trial on adjuvant immunotherapy with anti-PD1 antibody Pembrolizumab vs placebo after compete resection of high-risk stage III melanoma (EORTC), PI

Biopsy- and Biology-driven Optimization of Targeted Therapy of Metastatic Melanoma (BOTTOM) in BRAF inhibitor non-pretreated and pretreated subjects with advanced, nonresectable (stage IIIc) or metastatic (stage IV) BRAF V600E/K mutation-positive melanoma, PI

A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of Disease – IMMUNED, PI

Phase II trial to evaluate the correlation between objective response rate and baseline intratumoral CD8+ cell density in subjects with unresected stage IIIB to IVM1c melanoma treated with T-VEC, PI

Phase IIIb/IV randomized double blinded study of Nivolumab 3 mg/kg in combination with Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in combination with Ipilimumab 3 mg/kg in subjects with previously untreated, unresectable or Metastatic Melanoma (CheckMate 511), PI

A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melanoma (IMCgp100-201), PI

A Phase II, Multicenter, Open-Label, Randomized-Controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib plus Vemurafenib Followed by Immunotherapy with an Anti-PD-L1 Antibody Atezolizumab for the Treatment in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma (ImmunoCobiVem), PI

A phase III, double-blinded, randomized, placebo-controlled study of Atezolozumab plus Comimetinib and Vemurafenib vs placebo plus Cobimetinib and Vemurafenib in previously untreated BRAF V600 mutations-positive patients with unresectable locally advanced or metastatic melanoma (Trilogy), PI

A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915), PI

A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001 plus dabrafenib and trametinib versus placebo plus dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma (Combi-I), PI

A pivotal Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients (Pivotal), PI

An open-label Phase Ib/ II, multi-center study of 4SC-202 in Combination with Pembrolizumab in Patients with Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma primary refractory/non-responding to prior Anti-PD-1 Therapy (SENSITIZE), PI

Feasibility of Exercise as a supportive Measure for Patients undergoing Checkpoint-inhibitor Treatment (Sportivumab), IIT, PI

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma (IMCgp100-102), PI

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma (IMCgp100-202), PI

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma (CheckMate 047)

An open-label phase II multicenter study of vemurafenib (Zelboraf®) plus cobimetinib (Cotellic®) after radiosurgery in patients with active BRAF-V600-mutant melanoma brain metastases (RadioCoBRIM), PI

Eine offene Phase II-Studie zur Evaluierung der Sicherheit und Wirksamkeit einer Kombinationstherapie mit Ipilimumab und Nivolumab bei Patienten mit vier und mehr symptomatischen Hirnmetastasen eines Melanoms (BRAIN-IP), PI

Sekretariat Hauttumorzentrum Heidelberg

Öffnungszeiten
Mo – Do 08:00 – 16:00  
Fr 08:00 – 14:00  
Sekretäre/-innen